Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time.

BACKGROUND AND OBJECTIVE Meta-analyses of randomized trials may incorporate new evidence, and estimated treatment effects changeover time. We evaluated whether the certainty and estimates of efficacy and tolerability of mental health interventions change over time, as more trials appear on the same topics. METHODS One hundred meta-analyses (1,024 trial entries; 99,303 participants) with an outcome of death, relapse, failure or dropout and with five or more trials published in three or more different years were examined with cumulative meta-analysis and recursive cumulative meta-analysis. RESULTS Eight meta-analyses reached formal statistical significance (P < .05) at some point, but lost this significance eventually when more trials were published; typically large effect sizes in early trials were dissipated with further evidence. With 500 randomized subjects,95% of the time, subsequent changes in odds ratio might be up to 1.5-fold. For death, relapse, and failure outcomes, a decrease in effect size was somewhat more common than an increase, when more data became available (157 vs. 125, P = .06). This was most clear for comparisons of pharmacotherapies versus placebo (79 vs. 51, P = .009). CONCLUSIONS Evidence based on a small number of randomized subjects should be interpreted cautiously. Early treatment efficacy of pharmacotherapies is occasionally overestimated.

[1]  C. Adams,et al.  Content and quality of 2000 controlled trials in schizophrenia over 50 years , 1998, BMJ.

[2]  T C Chalmers,et al.  Cumulative meta-analysis of therapeutic trials for myocardial infarction. , 1992, The New England journal of medicine.

[3]  J. Ioannidis Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. , 1998, JAMA.

[4]  S. Leucht,et al.  Dropout rates in randomised antipsychotic drug trials , 2001, Psychopharmacology.

[5]  C H Schmid,et al.  Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. , 1995, Journal of clinical epidemiology.

[6]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[7]  J. Ioannidis,et al.  Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[9]  A R Feinstein,et al.  Meta-analysis: statistical alchemy for the 21st century. , 1995, Journal of clinical epidemiology.

[10]  John P A Ioannidis,et al.  Number of published systematic reviews and global burden of disease: database analysis , 2003, BMJ : British Medical Journal.

[11]  P. Langhorne,et al.  Revisiting the Cochrane Collaboration , 2001, BMJ : British Medical Journal.

[12]  J. Ioannidis,et al.  Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data. , 1999, Journal of clinical epidemiology.

[13]  Peter Jüni,et al.  Direction and impact of language bias in meta-analyses of controlled trials: empirical study. , 2002, International journal of epidemiology.

[14]  R. Rosenheck,et al.  Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia. , 2000, Psychiatric services.

[15]  G A Colditz,et al.  Understanding research synthesis (meta-analysis). , 1996, Annual review of public health.

[16]  M. Clarke,et al.  A comparison of handsearching versus MEDLINE searching to identify reports of randomized controlled trials , 2002, Statistics in medicine.

[17]  T C Chalmers,et al.  Changes in clinical trials mandated by the advent of meta-analysis. , 1996, Statistics in medicine.